Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315.

Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjørnsson B

Cancer immunology, immunotherapy : CII28 Mar 2014Cited by 78 (Europe PMC)

PMID24676901PMCIDPMC4024132DOI10.1007/s00262-014-1540-0PepBankPUB-24676901

Summary

Malignant melanoma is the most aggressive and deadliest form of skin cancer due to its highly metastatic potential, which calls for new and improved therapies. Cationic antimicrobial peptides (CAPs) are naturally occurring molecules found in most species, in which they play a significant role in the first line of defense against pathogens, and several CAPs have shown promising potential as novel anticancer agents. Structure-activity relationship studies on the CAP bovine lactoferricin allowed us to de novo design short chemically modified lytic anticancer peptides. In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice. Intratumoral administration of LTX-315 resulted in tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete regression of the tumor in the majority of the animals. LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1β, IL6 and IL18 in vivo. Animals cured by LTX-315 treatment were protected against a re-challenge with live B16 tumor cells both intradermally and intravenously. Together, our data indicate that intratumoral treatment with LTX-315 can provide local tumor control followed by protective immune responses and has potential as a new immunotherapeutic agent.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with B16 melanomas, intratumoral LTX‑315 induced tumor necrosis.
In plain wordsIn mice with melanoma, LTX‑315 induced tumor necrosis.
Peptide
LTX-315
Outcome
IncreaseTumor necrosis
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
Intratumoral administration of LTX-315 resulted in tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete regression of the tumor in the majority of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690101
02AnimalAnimal study (in vivo)Mechanism
In mice with B16 melanomas, LTX‑315 induced immune cell infiltration into tumor parenchyma.
In plain wordsIn mice with melanoma, LTX‑315 induced immune cell entry into tumors.
Peptide
LTX-315
Outcome
IncreaseImmune cell infiltration
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Immune response · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
Intratumoral administration of LTX-315 resulted in tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete regression of the tumor in the majority of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690102
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with B16 melanomas, LTX‑315 produced complete tumor regression in the majority of animals.
In plain wordsIn mice with melanoma, tumors disappeared in most animals after LTX‑315 treatment.
Peptide
LTX-315
Outcome
DecreaseComplete tumor regression
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
Intratumoral administration of LTX-315 resulted in tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete regression of the tumor in the majority of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690103
04AnimalAnimal study (in vivo)Mechanism
In mice, LTX‑315 induced upregulation of IL1β.
In plain wordsIn mice, LTX‑315 increased IL1β.
Peptide
LTX-315
Outcome
IncreaseIL1β upregulation
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Inflammation markers · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1β, IL6 and IL18 in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690105
05AnimalAnimal study (in vivo)Mechanism
In mice, LTX‑315 induced upregulation of IL6.
In plain wordsIn mice, LTX‑315 increased IL6.
Peptide
LTX-315
Outcome
IncreaseIL6 upregulation
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Inflammation markers · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1β, IL6 and IL18 in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690106
06AnimalAnimal study (in vivo)Mechanism
In mice, LTX‑315 induced upregulation of IL18.
In plain wordsIn mice, LTX‑315 increased IL18.
Peptide
LTX-315
Outcome
IncreaseIL18 upregulation
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Inflammation markers · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1β, IL6 and IL18 in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690107
07AnimalAnimal study (in vivo)Efficacy outcome
Mice cured by LTX‑315 were protected against intradermal rechallenge with live B16 cells.
In plain wordsIn mice cured by LTX‑315, protection persisted against skin rechallenge with live melanoma cells.
Peptide
LTX-315
Outcome
IncreaseProtection against intradermal tumor rechallenge
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Immune response · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
Animals cured by LTX-315 treatment were protected against a re-challenge with live B16 tumor cells both intradermally and intravenously.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690108
08AnimalAnimal study (in vivo)Efficacy outcome
Mice cured by LTX‑315 were protected against intravenous rechallenge with live B16 cells.
In plain wordsIn mice cured by LTX‑315, protection persisted against intravenous rechallenge with live melanoma cells.
Peptide
LTX-315
Outcome
IncreaseProtection against intravenous tumor rechallenge
Study
Mousen: not reported in source
B16 melanoma
Outcome group
Immune response · Cancer
Studied dose
Dose not stated · intratumoralAs given in this study (Mouse).
Source sentences
Summary
Animals cured by LTX-315 treatment were protected against a re-challenge with live B16 tumor cells both intradermally and intravenously.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice.
Show in the study text Report a problemFND-2467690109
09LabIn vitro (cells)Mechanism
In vitro, LTX‑315 induced release of danger-associated molecules including high mobility group box-1 protein.
In plain wordsIn lab tests, LTX‑315 induced release of the danger signal HMGB1.
Peptide
LTX-315
Outcome
IncreaseHMGB1 release
Study
n: not reported in source
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro
Show in the study text Report a problemFND-2467690104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.